- Cooperation with MSK therapy acceleration program includes manufacturing, IND and clinical development support for the Bria-OTS+™ platform, which includes Bria-BRES+™ for the treatment of breast cancer.
PHILADELPHIA and VANCOUVER, British Columbia, October 21, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or “Company“), a clinical-stage biotechnology company that is developing novel immunotherapies to transform cancer treatment, is pleased to announce a collaboration with Memorial Sloan Kettering Cancer Center's (MSK) Therapeutics Accelerator Cohort program to accelerate the clinical development of Bria-OTS+, a personalized off-the-shelf next-generation immunotherapy BriaCell for the treatment of various cancers, including metastatic breast cancer, prostate cancer and other cancers.
The collaboration begins with manufacturing, IND development and clinical protocol support for the phase 1 clinical trial of Bria-BRES+, BriaCell's next-generation personalized immunotherapy for breast cancer patients on the Bria-OTS+ platform. The partnership expands BriaCell's previously announced selection in MSK Accelerator Program.
As one of the world's leading institutions for cancer research and treatment, MSK has been a leader in patient care, education and discovery for more than 135 years. Through the MSK Therapeutics Accelerator, MSK's strategic therapeutic collaboration program, BriaCell will have access to MSK's clinical and institutional expertise, including cell therapy manufacturing, investigational new drug (IND) preparation and submission, and clinical development to accelerate platform development Bria-OTS+.
“We are thrilled to partner with MSK’s scientific and clinical experts to address the urgent unmet medical needs of many thousands of patients with metastatic breast cancer,” said Dr. William W. Williams, President and CEO of BriaCell.
“We are honored to work with the oncology team at MSK,” said Miguel Lopez-Lago, Ph.D., chief scientific officer of BriaCell. “This collaboration with MSK will accelerate the development of our advanced off-the-shelf personalized immunotherapy platform, Bria-OTS+, which we believe has the potential to transform cancer treatment and significantly improve the lives of patients through its unique mechanism of action.”
“We look forward to collaborating with BriaCell through MSK's Therapeutics Accelerator to help advance this next generation of personalized immunotherapy into the clinic. Collaborations like these are essential for translating promising scientific innovations into potentially new treatment options for patients,” said Shanu Mody, MD, breast oncologist. glands and MSK attending physician.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company developing new immunotherapies to transform cancer treatment. Additional information can be obtained at https://briacell.com/.
About the MSK Therapeutics accelerator
Through the Therapeutics Accelerator program, MSK partners with biotechnology companies to help advance innovative cancer treatments from early development to the clinic. By combining the resources of leading healthcare companies with MSK's world-renowned clinical and scientific expertise, the program fosters collaborations aimed at improving cancer care and cures. For more information see here: Accelerators and Commercialization Programs: MSK Therapeutics Accelerator | Memorial Sloan-Kettering Cancer Center .
Memorial Sloan Kettering (MSK) has institutional financial interests related to BriaCell.
Safe Harbor
This press release contains “forward-looking statements” that involve significant risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release can be identified by the use of words such as “expect”, “believe”, “consider”, “may”, “estimate”, “anticipate”, “intend”, “seek”, “could”, “could”, “plan”, “potential”, “forecast”, “project”, “target”, “target”, “should”, “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release, including statements regarding the Company's belief that the collaboration with Memorial Sloan-Kettering Cancer Center can advance the clinical development of Bria-OTS+; the specific areas that the MSK Therapeutics Accelerator group will study; the Company's access to MSK's experience and institutional resources; and the Company's beliefs regarding the potential of Bria-OTS+ to transform cancer treatment and offer significant improvements in efficacy and safety for thousands of patients are based on assumptions about future events that may prove to be inaccurate. These and other risks and uncertainties are described in more detail under the heading “Risks and Uncertainties” in the most recent Management's Discussion and Analysis, under the heading “Risk Factors” in the Company's most recent annual information form and under the heading “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulators and the U.S. Securities and Exchange Commission, all of which are available under profiles Companies on SEDAR+ at www.sedarplus.ca and about EDGAR in www.sec.gov. The forward-looking statements contained in this announcement are made as of this date and BriaCell Therapeutics Corp. does not undertake any obligation to update such information, except as required by applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact information
Company contact information:
William W. Williams, MD
President and CEO
1-888-485-6340
[email protected]
Investor Relations Contact:
[email protected]
